UY37511A - Anticuerpos y polipéptidos dirigidos contra cd127 - Google Patents

Anticuerpos y polipéptidos dirigidos contra cd127

Info

Publication number
UY37511A
UY37511A UY0001037511A UY37511A UY37511A UY 37511 A UY37511 A UY 37511A UY 0001037511 A UY0001037511 A UY 0001037511A UY 37511 A UY37511 A UY 37511A UY 37511 A UY37511 A UY 37511A
Authority
UY
Uruguay
Prior art keywords
antibodies
directed against
polypeptides directed
applications
diagnostic
Prior art date
Application number
UY0001037511A
Other languages
English (en)
Inventor
Caroline Mary
Nicolas Poirier
Virginie Thepenier
Bernard Vanhove
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of UY37511A publication Critical patent/UY37511A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se encuentra el campo de los anticuerpos útiles en aplicaciones terapéuticas y de diagnóstico con diana en CD127, la cadena alfa del receptor de IL7, y provee en particular, anticuerpos monoclonales humanizados contra CD127, particularmente CD127 humano, sus usos terapéuticos y aplicaciones de tipo diagnóstico.
UY0001037511A 2016-12-09 2017-12-07 Anticuerpos y polipéptidos dirigidos contra cd127 UY37511A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16306655 2016-12-09

Publications (1)

Publication Number Publication Date
UY37511A true UY37511A (es) 2018-06-29

Family

ID=57796143

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037511A UY37511A (es) 2016-12-09 2017-12-07 Anticuerpos y polipéptidos dirigidos contra cd127

Country Status (37)

Country Link
US (2) US11098128B2 (es)
EP (1) EP3551664B1 (es)
JP (1) JP6986559B2 (es)
KR (1) KR102306366B1 (es)
CN (1) CN110392695B (es)
AR (1) AR110326A1 (es)
AU (1) AU2017373819B2 (es)
BR (1) BR112019010595A2 (es)
CA (1) CA3042582C (es)
CL (1) CL2019001530A1 (es)
CO (1) CO2019005909A2 (es)
CR (1) CR20190273A (es)
CY (1) CY1124153T1 (es)
DK (1) DK3551664T3 (es)
EA (1) EA201991005A1 (es)
ES (1) ES2867900T3 (es)
HR (1) HRP20210697T1 (es)
HU (1) HUE054206T2 (es)
IL (1) IL266837B (es)
LT (1) LT3551664T (es)
MA (1) MA49727B1 (es)
MD (1) MD3551664T2 (es)
MX (1) MX2019006577A (es)
MY (1) MY190770A (es)
NZ (1) NZ753213A (es)
PE (1) PE20191152A1 (es)
PH (1) PH12019501285A1 (es)
PL (1) PL3551664T3 (es)
PT (1) PT3551664T (es)
RS (1) RS61808B1 (es)
RU (1) RU2769352C2 (es)
SA (1) SA519401906B1 (es)
SI (1) SI3551664T1 (es)
TW (1) TWI777996B (es)
UA (1) UA126386C2 (es)
UY (1) UY37511A (es)
WO (1) WO2018104483A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3066054A1 (en) 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer therapy and kit therefor
JP7285936B2 (ja) 2019-01-22 2023-06-02 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用
MX2021015763A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polipeptidos.
JP2022537780A (ja) 2019-06-21 2022-08-29 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
JP7427286B2 (ja) 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド ＩＬ－２ＲβγＣ結合化合物
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
MX2022009390A (es) * 2020-02-03 2022-11-16 Medikine Inc Compuestos de unión a il-7r¿¿c.
US20220389104A1 (en) 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
CN113501499A (zh) * 2021-08-11 2021-10-15 无锡贝塔医药科技有限公司 一种高纯无水溴化氘气体的制备方法及其应用
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2023232826A1 (en) 2022-05-30 2023-12-07 Ose Immunotherapeutics Biomarkers of il7r modulator activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32038A (es) * 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
PE20121702A1 (es) * 2010-01-28 2012-12-14 Glaxo Group Ltd Proteinas de enlace cd127
US8298535B2 (en) * 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies
EP2583980A1 (en) 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
HUE054206T2 (hu) 2021-08-30
AR110326A1 (es) 2019-03-20
CL2019001530A1 (es) 2019-10-11
US20190375844A1 (en) 2019-12-12
UA126386C2 (uk) 2022-09-28
KR102306366B1 (ko) 2021-09-29
HRP20210697T1 (hr) 2021-07-23
US20220332834A2 (en) 2022-10-20
PH12019501285A1 (en) 2019-12-16
CO2019005909A2 (es) 2019-07-31
TW201833137A (zh) 2018-09-16
AU2017373819B2 (en) 2022-03-31
MY190770A (en) 2022-05-12
TWI777996B (zh) 2022-09-21
SA519401906B1 (ar) 2022-12-20
MX2019006577A (es) 2019-10-07
BR112019010595A2 (pt) 2019-09-17
IL266837B (en) 2020-06-30
RU2019115610A3 (es) 2021-04-05
CN110392695B (zh) 2021-02-02
AU2017373819A1 (en) 2019-05-30
MD3551664T2 (ro) 2021-06-30
MA49727A (fr) 2019-10-16
RU2019115610A (ru) 2021-01-12
JP6986559B2 (ja) 2022-01-05
WO2018104483A1 (en) 2018-06-14
DK3551664T3 (da) 2021-05-03
EA201991005A1 (ru) 2019-12-30
PL3551664T3 (pl) 2021-08-02
US20210395376A1 (en) 2021-12-23
EP3551664B1 (en) 2021-02-17
RU2769352C2 (ru) 2022-03-30
LT3551664T (lt) 2021-05-25
JP2020500542A (ja) 2020-01-16
IL266837A (en) 2019-07-31
MA49727B1 (fr) 2021-05-31
EP3551664A1 (en) 2019-10-16
CY1124153T1 (el) 2022-05-27
PE20191152A1 (es) 2019-09-05
CA3042582C (en) 2023-05-23
KR20190090005A (ko) 2019-07-31
CA3042582A1 (en) 2018-06-14
US11926671B2 (en) 2024-03-12
SI3551664T1 (sl) 2021-08-31
ES2867900T3 (es) 2021-10-21
PT3551664T (pt) 2021-04-21
RS61808B1 (sr) 2021-06-30
US11098128B2 (en) 2021-08-24
CN110392695A (zh) 2019-10-29
CR20190273A (es) 2019-10-17
NZ753213A (en) 2022-05-27

Similar Documents

Publication Publication Date Title
CO2019005909A2 (es) Anticuerpos y polipéptidos dirigidos contra cd127
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
SV2018005683A (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos
PE20170441A1 (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
CO2020013392A2 (es) Receptores quiméricos de dll3 y métodos para su uso
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2017013235A2 (es) Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral ox40
ES2972137T3 (es) Conjugados de polipéptidos de interleucina-2 y sus usos
CO2017009061A2 (es) Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenes
CO2020014345A2 (es) Anticuerpos específicos para gucy2c y sus usos
EA201891589A1 (ru) Условно активные гетеродимерные полипептиды и способы их применения
CO2017001191A2 (es) Conjugados de fármacos con anticuerpos anti-cdh6
CL2018000728A1 (es) Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
CL2016002247A1 (es) Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
ECSP17003946A (es) Anticuerpos antagonistas del interferón alfa y omega
BR112017015880A2 (pt) anticorpos, usos e métodos
EA202091521A1 (ru) ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
ECSP22019177A (es) Proteínas de fusión nkg2d y sus usos
IT201700115761A1 (it) Bioreattore per la ricellularizzazione e la stimolazione meccanica del diaframma
AR119973A1 (es) Composiciones y métodos de anticuerpos anti-cd39
AR119984A1 (es) Proteínas de fusión nkg2d y sus usos